Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending
Vaxcyte (PCVX) shares fell by 9.7% after the company reported steeper first-quarter 2026 losses of US$320.62 million, driven by accelerated R&D spending to advance its vaccine pipeline, particularly the VAX 31 Phase 3 trials. The significant increase in spending highlights the company's aggressive strategy to bring products to market while still pre-revenue, emphasizing the importance of future clinical trial outcomes for its financial trajectory. Despite the short-term losses, Vaxcyte's narrative projects substantial revenue and earnings growth by 2029, suggesting a significant upside according to some fair value estimates.
Vaxcyte Inc stock (US92242T1016): fresh data from pneumococcal vaccine program keeps biotech in focu
Vaxcyte Inc. has garnered investor attention with advancements in its next-generation pneumococcal conjugate vaccine program and recent financing activities. The company, a clinical-stage vaccine specialist, focuses on developing protein-conjugate and other vaccines using an engineered cell-free protein synthesis platform. Its lead candidate, VAX-24, targets pneumococcal disease, aiming for broader serotype coverage than existing vaccines, and the company's future revenue heavily relies on its clinical success and eventual market approval.
Vaxcyte stock (US92242T1016): Pneumococcal vaccine data keeps investors focused
Vaxcyte (PCVX) is a clinical-stage biotechnology company focused on developing next-generation pneumococcal vaccines, which remains its primary value driver. The company's stock is highly sensitive to clinical trial updates, regulatory milestones, and financing signals, as it operates without significant product revenue. For U.S. investors, Vaxcyte represents a catalyst-driven healthcare story amidst competition in the vaccine innovation sector, subject to biotech risks like dilution and trial setbacks.
RA Capital reports 12.97M shares in Vaxcyte (NASDAQ: PCVX)
RA Capital Management, through its related reporting persons, has disclosed beneficial ownership of 12,974,599 shares of Vaxcyte (NASDAQ: PCVX) common stock as of March 31, 2026. This ownership includes direct holdings by RA Capital Healthcare Fund and RA Capital Nexus Fund, as well as pre-funded warrants. The reporting persons, including Peter Kolchinsky and Rajeev Shah, collectively represent 8.9% of Vaxcyte's outstanding shares.
Janus Henderson (PCVX) discloses 16.6M shares, 11.5% ownership
Janus Henderson Group plc has filed an amendment to disclose its beneficial ownership of 16,575,875 shares of Vaxcyte, Inc. common stock, representing an 11.5% stake as of March 31, 2026. The asset managers exercise shared voting and dispositive power over these shares on behalf of managed client portfolios. However, Janus Henderson disclaims any rights to dividends or sale proceeds, indicating that the economic ownership rests with their clients.
(PCVX) Movement Within Algorithmic Entry Frameworks
Vaxcyte Inc. (PCVX) is showing positive near-term sentiment within a long-term strong context, despite a weak mid-term bias. Algorithmic analysis reveals an exceptional 41.9:1 risk-reward setup, targeting an 11.8% gain with a 0.3% risk. The article provides specific entry and target zones for long, breakout, and short positions based on AI-generated institutional trading strategies.
Vaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund D
The State of New Jersey Common Pension Fund D significantly reduced its stake in Vaxcyte, Inc. by 40.2% in the fourth quarter, selling 26,778 shares and holding 39,880 shares valued at $1.84 million. This reduction comes despite Vaxcyte reporting a wider-than-expected quarterly loss and an anticipated full-year loss of -$7.46 per share. Despite some insider and fund reductions, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $86.
Assessing Vaxcyte (PCVX) Valuation After Key VAX 31 Trial Milestones And Balance Sheet Update
Vaxcyte (PCVX) reported a significant net loss in Q1 but is advancing its VAX-31 vaccine trials and plans a VAX-A1 study. Despite recent share price declines, the company shows strong long-term performance, and Simply Wall St assesses it as 52.8% undervalued with a narrative fair value of $109, contingent on successful clinical trials and manufacturing. The article suggests that expanded adult pneumococcal vaccination recommendations increase the addressable market for VAX-31.
Nan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVX
Nan Fung Trinity HK Ltd. significantly increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 37.1% in the fourth quarter, purchasing an additional 38,680 shares to bring its total ownership to 142,930 shares valued at approximately $6.6 million. Despite some mixed analyst sentiment and recent insider share sales, the stock holds a "Moderate Buy" consensus rating with an average target price of $86.00, reflecting optimism for the biotechnology company focused on preventive vaccines. Institutional ownership in Vaxcyte remains high at 96.78%, while the company's Q4 earnings missed analyst estimates.
Assessing Vaxcyte (PCVX) Valuation After Key VAX 31 Trial Milestones And Balance Sheet Update
Vaxcyte (PCVX) reported a significant net loss in the first quarter, despite advancing VAX-31 vaccine trials and an upcoming VAX-A1 study. The stock has seen short-term declines but shows a strong long-term performance. While analysts suggest it's undervalued with a fair value of $109, this valuation relies heavily on the successful commercialization of its vaccine pipeline and could be challenged by clinical setbacks or cost overruns.
Vaxcyte, Inc. $PCVX Shares Purchased by UBS Group AG
UBS Group AG increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 29% in the fourth quarter, acquiring an additional 246,020 shares to hold a total of 1,093,593 shares worth approximately $50.46 million. Despite this institutional buying, company insiders have sold 17,037 shares totaling nearly $1 million over the past 90 days. Vaxcyte, a clinical-stage biotech company with an $8.03 billion market cap, holds an average "Moderate Buy" rating from analysts with an average price target of $86.00, despite recently missing EPS expectations.
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116
Guggenheim has reiterated its Buy rating for Vaxcyte (PCVX.US) and maintained a target price of $116. This continued positive outlook suggests the firm sees strong potential in Vaxcyte's stock.
Vaxcyte (PCVX) Is Down 10.1% After Wider Q1 Loss But Completing Key VAX-31 Phase 3 Enrollment
Vaxcyte (PCVX) experienced a 10.1% stock drop after reporting a wider net loss of US$320.62 million in Q1 2026. Despite the financial setback, the company made significant pipeline progress by completing enrollment for its VAX-31 adult Phase 3 trials and initiating plans for a Phase 1 study for its VAX-A1 Group A Strep vaccine candidate. This advancement keeps the short-term catalyst of the OPUS-1 readout in late 2026 intact, while also highlighting the ongoing challenge of cash burn and potential future financing needs.
Vaxcyte slides after Q1 loss widens as spending ramps ahead of key Phase 3 readouts
Vaxcyte (PCVX) shares fell 9.8% after reporting a significantly wider first-quarter net loss of $320.6 million due to increased R&D and manufacturing expenses for its late-stage pneumococcal vaccine trials. Despite a substantial cash balance, rising burn rate combined with a recent equity offering impacted investor sentiment. The company expects the first topline data from its Phase 3 OPUS trials for VAX-31 in Q4 2026.
Vaxcyte’s VAX-31 Advances With Three Phase 3 Trials Enrolling 6,191 Adults
Vaxcyte's VAX-31, a pneumococcal conjugate vaccine, has progressed with three fully enrolled Phase 3 trials involving 6,191 adults. The OPUS-1 trial is a noninferiority study comparing VAX-31 against Prevnar 20 and Capvaxive, aiming to demonstrate superior serotype coverage. The outcome of the immunogenicity data, expected in Q4 2026, will be crucial in defining VAX-31's market position and potential to reframe the PCV market.
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte, Inc. announced its first quarter 2026 financial results, highlighting the completion of enrollment for its VAX-31 Phase 3 adult clinical trials (OPUS-1, OPUS-2, and OPUS-3) and infant Phase 2 study. The company anticipates topline data from OPUS-1 in Q4 2026 and from OPUS-2 and OPUS-3 in H1 2027, with a Biologics License Application (BLA) submission planned. Vaxcyte also plans to initiate a Phase 1 adult study for its Group A Strep vaccine candidate, VAX-A1, in mid-2026, and reported a strong cash position of approximately $2.7 billion.
Vaxcyte (NASDAQ: PCVX) advances Phase 3 VAX-31 program and holds $2.7B cash
Vaxcyte reported its Q1 2026 financial results, highlighting the advancement of its VAX-31 Phase 3 adult clinical program, which is now fully enrolled, and the completion of enrollment for its infant Phase 2 study. The company maintained a strong cash position of $2.74 billion as of March 31, 2026, following a February equity offering. Despite a widening net loss to $320.6 million due to increased R&D spending, Vaxcyte is progressing with manufacturing and plans to initiate a Phase 1 adult study for its VAX-A1 Group A Strep vaccine candidate in mid-2026.
FMR LLC discloses 11.4% stake in Vaxcyte (NASDAQ: PCVX)
FMR LLC has disclosed an 11.4% stake in Vaxcyte (NASDAQ: PCVX), representing beneficial ownership of 16,451,061.32 shares. This information comes from an Amendment No. 9 to a Schedule 13G/A filing, which details voting and dispositive powers held by FMR LLC and Abigail P. Johnson. The filing is administrative and does not indicate a transaction, but rather clarifies ownership structure and authorities.
Vaxcyte, Inc. (PCVX) Investor Outlook: Analyzing a 91% Potential Upside in the Biotech Sector
Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company with a promising portfolio of vaccine candidates and a potential upside of 91.46%. Despite being in a pre-revenue stage with a significant free cash flow deficit due to R&D investments, analysts are largely optimistic, projecting an average target price of $109.00. The company's strategic focus on conjugate vaccines positions it for growth within the healthcare sector, particularly given emerging global health challenges, though investors should consider the inherent risks of biotech investments.
How (PCVX) Movements Inform Risk Allocation Models
Vaxcyte Inc. (NASDAQ: PCVX) is showing weak near and mid-term sentiment but retains a strong long-term outlook. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—to optimize position sizing and manage drawdown risk. The analysis highlights a significant 34.1:1 risk-reward short setup, targeting a 9.8% downside against a 0.3% risk.
Jennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVX
Jennison Associates LLC reduced its stake in Vaxcyte, Inc. by 42.1% in the fourth quarter, selling nearly 500,000 shares but still holding 677,553 shares valued at approximately $31.26 million. Despite a "Moderate Buy" consensus from analysts, Vaxcyte remains unprofitable, reporting an EPS of -$1.80 for its latest quarter, and company insiders sold shares worth almost $1 million. The company, which has a market capitalization of $8.22 billion, is focused on developing new preventive vaccines.
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX)
Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (PCVX), sold 2,250 shares of the company on May 1, 2026. This transaction continues a trend within the company, with 8 insider sells and no insider buys recorded over the past year. Following the sale, Wassil now holds 160,744 shares, while Vaxcyte Inc's shares were trading at $56.83, giving it a market cap of $8.22 billion.
Vaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in Stock
Vaxcyte (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the company's stock on May 1st for $127,867.50, executed under a pre-arranged Rule 10b5-1 trading plan. This sale reduced his stake by 1.38% to 160,744 shares. The company recently reported a quarterly EPS of ($1.80), missing estimates, and holds a "Moderate Buy" consensus rating from analysts with an $86.00 price target.
Vaxcyte (PCVX) COO Jim Wassil sells 2,250 shares in Rule 10b5-1 trade
Vaxcyte's Chief Operating Officer, Jim Wassil, sold 2,250 shares of common stock at a weighted-average price of $56.831 per share. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, adopted on December 9, 2025. Following this sale, Wassil directly holds 160,744 shares of Vaxcyte common stock.
PCVX (PCVX) insider James Wassil files planned sales totaling $566,913.91
PCVX insider James Wassil has filed Form 144 for planned sales of company common stock, totaling $566,913.91. This includes two notices: 7,395 shares for $435,438.31 dated March 10, 2026, and 2,250 shares for $131,475.60 dated April 1, 2026. The filing also details recent issuer vesting events such as RSU vests and ESPP shares, indicating both past and future stock acquisitions.
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares
Vaxcyte (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the company's common stock for a total of $127,869 on May 1, 2026. The sales were executed under a Rule 10b5-1 trading plan. The transaction occurred as Vaxcyte shares have seen a 61.55% return over the past year, though the stock is considered slightly overvalued.
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVX
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 105.3% in the fourth quarter, now holding 70,124 shares valued at $3.24 million. Despite the company missing its quarterly EPS estimates and analysts projecting a significant full-year loss, Vaxcyte maintains a "Moderate Buy" consensus rating with an average target price of $86. Insider selling activity has been noted, while institutional investors hold the vast majority of the company's stock.
Pictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVX
Pictet Asset Management Holding SA significantly reduced its stake in Vaxcyte, Inc. by 14.4% in Q4, selling 148,194 shares and ending the period with 881,435 shares valued at $40.67 million. Meanwhile, Vaxcyte insiders have also been selling shares, with 14,787 shares worth $867,031 disposed of over the past 90 days. Analyst sentiment for PCVX is a "Moderate Buy" with an average price target of $86.00, despite the company missing its Q4 earnings estimates.
Vanguard (PCVX) holds 7.25M Vaxcyte shares, reports 5.03% stake
Vanguard Capital Management has reported a beneficial ownership of 7,252,053 shares of Vaxcyte Inc. common stock, which represents a 5.03% stake in the company. The Schedule 13G filing indicates Vanguard has sole power to dispose of all 7.25 million shares and sole voting power over 985,352 shares. This disclosure, signed on April 30, 2026, reflects a passive investment by the large manager and does not imply any operational changes at Vaxcyte or immediate trading intent.
Vaxcyte (PCVX) Expected to Announce Quarterly Earnings on Wednesday
Vaxcyte (NASDAQ:PCVX) is projected to release its Q1 2026 earnings after market close on Wednesday, May 6th, with analysts forecasting an EPS of ($1.7411) and revenue of $12.5 million. The company's stock currently trades around $58.73, with a market capitalization of $8.48 billion, and has seen mixed analyst ratings but high institutional ownership. Recent insider selling has been noted, while major institutional investors have increased their stakes.
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring the 83% Potential Upside in Vaccine Innovation
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing novel vaccines for bacterial infectious diseases, with a significant lead candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine. Analysts are overwhelmingly positive, with an average price target of $109, implying an 83.22% potential upside. Despite being in a growth stage with negative free cash flow, the company's strong pipeline and strategic focus on unmet medical needs position it as an intriguing opportunity for investors willing to consider the inherent risks of biotech development.
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages
Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus "Moderate Buy" rating from eight brokerages, with an average one-year price target of $86.00. The company recently reported a quarterly EPS of ($1.80), missing estimates, and analysts project a full-year EPS of -7.00. Insiders have sold approximately 14,787 shares in the last 90 days, while institutional investors own a significant 96.78% of the stock.
Vaxcyte Completes Enrollment for Phase 3 VAX-31 Vaccine Trials
Vaxcyte Inc. (NASDAQ: PCVX) has announced the completion of participant enrollment for two Phase 3 clinical trials, OPUS-1 and OPUS-2, evaluating its VAX-31 vaccine candidate for invasive pneumococcal disease in adults. The OPUS-1 study, with 4,000 participants, focuses on safety and immune response, with results expected in Q4 2026, while the 1,300-participant OPUS-2 study investigates co-administration with influenza vaccine, with results anticipated in H1 2027. This milestone follows a significant $600 million equity financing round and a strong financial position to support its development efforts.
[ARS] Vaxcyte, Inc. SEC Filing
This article announces an ARS SEC filing by Vaxcyte, Inc. (PCVX) on April 23, 2026. The filing has a low impact and neutral sentiment. The article also provides a company overview, recent news, and other SEC filings for Vaxcyte, Inc.
5 Best 52-Week High US Stocks to Buy
This article identifies five top-performing US stocks hitting 52-week highs, highlighting strong investment opportunities. It features Vaxcyte Inc. (NASDAQ:PCVX), detailing its Phase 3 clinical trials for a pneumococcal vaccine and its financial stability. The piece also includes a section on the projected $250 trillion AI market, promoting a report on an undervalued AI company.
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen
Vaxcyte's stock rating has been upgraded by Wall Street Zen from "strong sell" to "sell." Despite this upgrade, the overall analyst consensus remains positive with a "Moderate Buy" rating and a consensus price target of $86.00, significantly above its current price. However, the company missed its quarterly EPS estimates and insiders have sold off a notable amount of stock recently.
Insiders At Vaxcyte Sold US$1.0m In Stock, Alluding To Potential Weakness
Insiders at Vaxcyte (NASDAQ:PCVX) recently sold US$1.0 million worth of company stock over the last year, suggesting potential weakness. While insider selling doesn't always signal trouble, it can be a red flag when combined with a lack of significant insider buying. In Vaxcyte's case, the largest individual sale was by the CEO, although this represents a small portion of their holdings.
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110
Needham has reiterated its Buy rating for Vaxcyte (PCVX.US) and maintained its price target at $110. This indicates a continued positive outlook from the firm regarding Vaxcyte's stock performance.
PCVX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Vaxcyte Inc.'s (PCVX) financial performance, focusing on its profitability metrics and market positioning. It highlights the company's gross, operating, and net margins, as well as its Return on Equity. The article also includes a comparison of PCVX's efficiency against competitors TECH and ARWR, noting its market capitalization of $8.76 billion.
Vaxcyte CAO Sells $180,000 in Company Stock
Vaxcyte's Chief Accounting Officer, Elvia Cowan, sold 3,000 shares of company stock for $180,000 on April 7, 2026. This transaction reduced her ownership by 9.38% and was conducted under a pre-arranged Rule 10b5-1 trading plan. The sale provides insight into management's view of the company's valuation as Vaxcyte continues to develop preventive vaccines.
Vaxcyte Inc stock: Why its pneumococcal vaccine pipeline draws investor focus
Vaxcyte Inc is developing VAX-31, a next-generation pneumococcal vaccine targeting 31 serotypes to address unmet needs in adult immunization. The company's proprietary XpressCF technology aims to deliver stronger, longer-lasting immune responses, positioning VAX-31 to potentially outperform current market leaders. With Phase 3 trials underway, strong cash reserves, and bullish analyst sentiment, the biotech is drawing significant investor interest as it aims for regulatory approval and market disruption.
Vaxcyte CAO Sells $180,000 in Stock
Vaxcyte's Chief Accounting Officer, Elvia Cowan, sold 3,000 shares of company stock worth $180,000 as part of a pre-arranged trading plan. This transaction represents a 9.38% reduction in her holdings but is not necessarily indicative of future performance due to the pre-planned nature of the sale. Vaxcyte is a clinical-stage biotech company developing preventive vaccines.
Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise
Vaxcyte's SVP, Finance & CAO, Elvia Cowan, exercised stock options for 3,000 shares at $25.92 per share and subsequently sold all 3,000 shares at $60.00 per share on April 7, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. After the sale, Cowan holds 28,975 shares directly.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, a clinical-stage vaccine innovation company, announced its management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference. The event is scheduled for Tuesday, April 14, 2026, at 2:15 p.m. ET. A live webcast and replay will be available through the Investors & Media section of the Company’s website.
Vaxcyte Inc stock: Why its pneumococcal vaccine pipeline draws investor focus
Vaxcyte Inc is gaining investor attention due to its VAX-31 pneumococcal vaccine, which is currently in Phase 3 trials and aims to improve adult immunization by covering more serotypes than existing market leaders. The company boasts significant cash reserves, positioning it as a potential disruptor in the vaccine market. Success in late 2026 and early 2027 clinical readouts could validate its technology and broaden its market opportunities.
Vaxcyte to Present at Annual Healthcare Conference
Vaxcyte, Inc., a clinical-stage vaccine company, announced its management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026. This participation provides an opportunity for Vaxcyte to share updates on its innovative vaccine candidates, including VAX-31, VAX-24, and VAX-XL, which aim to offer broader protection against pneumococcal disease. The live webcast will be accessible through the Investors & Media section of Vaxcyte's website.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. announced that its management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The company is a clinical-stage vaccine innovation company, with its lead candidate VAX-31 being a 31-valent pneumococcal conjugate vaccine. Vaxcyte focuses on developing high-fidelity vaccines to protect against bacterial diseases using its XpressCF® cell-free protein synthesis platform.
Elvia Cowan registers 3,000-share sale (PCVX) after option exercise
Elvia Cowan has filed a Form 144 to report the proposed sale of 3,000 shares of Vaxcyte, Inc. (PCVX) common stock on April 7, 2026, stemming from an exercise of stock options with cash payment. The filing also details prior sales made by Cowan, including 2,500 shares on March 11, 2026, for $146,481.75 and 1,892 shares on March 17, 2026, for $105,146.20. An expert notes this is a typical procedure for affiliates converting derivatives and registering shares for resale under Rule 144.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, a clinical-stage vaccine innovation company, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. The company will present in a fireside chat on April 14, 2026, to discuss its pipeline of novel vaccine candidates, including VAX-31 and VAX-24, which aim to provide broader protection against pneumococcal disease. A live webcast and replay of the event will be available through the Investors & Media section of Vaxcyte's website.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. announced that its management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The clinical-stage company focuses on developing innovative vaccines, including advanced pneumococcal conjugate vaccine (PCV) candidates like VAX-31 and VAX-24, and leverages its XpressCF® platform for vaccine production. A live webcast and replay of the event will be available through the company's investors website.
